Characteristics of HPV-Specific Antibody Responses Induced by Infection and Vaccination: Cross-Reactivity, Neutralizing Activity, Avidity and IgG Subclasses

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Scherpenisse, Mirte ^a,b   Schepp, Rutger M ^a   Mollers, Madelief ^a,b   Meijer, Chris J L M ^b   Berbers, Guy A M ^a   van der Klis, Fiona R M ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN G4 ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; CHILD; CROSS REACTION; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMORAL IMMUNITY; IMMUNOASSAY; PAPILLOMAVIRUS INFECTION; PRESCHOOL CHILD; SCHOOL CHILD; SEROEPIDEMIOLOGY; WART VIRUS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; ANTIBODY FORMATION; CHILD; CHILD, PRESCHOOL; CROSS REACTIONS; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNOGLOBULIN G; INFANT; INFANT, NEWBORN; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SPECIES SPECIFICITY; VACCINATION; YOUNG ADULT;

EID: 84884266750     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074797     Document Type: Article

References (39)

1. Burk RD, Chen Z, Van Doorslaer K, (2009) Human papillomaviruses: genetic basis of carcinogenicity. Public Health Genomics 12: 281-290. doi:10.1159/000214919. PubMed: 19684441.
2. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H, (2004) Classification of papillomaviruses. Virology 324: 17-27. doi:10.1016/j.virol.2004.03.033. PubMed: 15183049.
3. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, et al. (2000) Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 181: 1911-1919. doi:10.1086/315498. PubMed: 10837170.
4. Roteli-Martins C, Naud P, De Borba P, Teixeira J, De Carvalho N, et al. (2012) Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin. J Immunother 8.
5. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, et al. (2011) Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol, 13: 89-99. PubMed: 22075171.
6. Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, et al. (2011) Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol, 13: 100-10. PubMed: 22075170.
7. Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y, et al. (2011) HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 29: 2011-2014. doi:10.1016/j.vaccine.2011.01.001. PubMed: 21241731.
8. Ho GY, Studentsov Y, Hall CB, Bierman R, Beardsley L, et al. (2002) Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 186: 737-742. doi:10.1086/342972. PubMed: 12198606.
9. Palmroth J, Namujju P, Simen-Kapeu A, Kataja V, Surcel HM, et al. (2010) Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes. Scand J Infect Dis 42: 379-384. doi:10.3109/00365540903501608. PubMed: 20121650.
10. De Carvalho N, Teixeira J, Roteli-Martins CM, Naud P, De Borba P, et al. (2010) Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 28: 6247-6255. doi:10.1016/j.vaccine.2010.07.007. PubMed: 20643092.
11. Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, et al. (2011) Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin 7: 1343-1358. doi:10.4161/hv.7.12.18281. PubMed: 22048173.
12. Scherpenisse M, Mollers M, Schepp RM, Boot HJ, de Melker HE, et al. (2012) Seroprevalence of seven high-risk HPV types in The Netherlands. Vaccine, 30: 6686-93. PubMed: 22959981.
13. Scherpenisse M, Mollers M, Schepp RM, Meijer CJ, de Melker HE, et al. (2012) Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination. Hum Vaccin Immunother 9([MedlinePgn:]) PubMed: 23149693.
14. Namujju PB, Hedman L, Hedman K, Banura C, Mbidde EK, et al. (2011) Low avidity of human papillomavirus (HPV) type 16 antibodies is associated with increased risk of low-risk but not high-risk HPV type prevalence. BMC Res Notes 4: 170. doi:10.1186/1756-0500-4-170. PubMed: 21645376.
15. Dauner JG, Pan Y, Hildesheim A, Harro C, Pinto LA, (2010) Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine. Vaccine 28: 5407-5413. doi:10.1016/j.vaccine.2010.06.018. PubMed: 20591543.
16. Kemp TJ, Safaeian M, Hildesheim A, Pan Y, Penrose KJ, et al. (2012) Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix((R)). Vaccine.
17. van der Klis FR, Mollema L, Berbers GA, de Melker HE, Coutinho RA, (2009) Second national serum bank for population-based seroprevalence studies in the Netherlands. Neth J Med 67: 301-308. PubMed: 19687529.
18. Braunstein SL, Ingabire CM, Kestelyn E, Uwizera AU, Mwamarangwe L, et al. (2011) High human immunodeficiency virus incidence in a cohort of Rwandan female sex workers. Sex Transm Dis 38: 385-394. doi:10.1097/OLQ.0b013e31820b8eba. PubMed: 22256340.
19. Mollers M, Scherpenisse M, van der Klis FR, King AJ, van Rossum TG, et al. (2012) Prevalence of genital HPV infections and HPV serology in adolescent girls, prior to vaccination. Cancer Epidemiol.
20. Anttila M, Eskola J, Ahman H, Käyhty H, (1998) Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J Infect Dis 177: 1614-1621. doi:10.1086/515298. PubMed: 9607841.
21. Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, et al. (2008) Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 4: 425-434. doi:10.4161/hv.4.6.6912. PubMed: 18948732.
22. Malagón T, Drolet M, Boily MC, Franco EL, Jit M, et al. (2012) Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12: 781-789. doi:10.1016/S1473-3099(12)70187-1. PubMed: 22920953.
23. Draper E, Bissett SL, Howell-Jones R, Edwards D, Munslow G, et al. (2011) Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera. Vaccine 29: 8585-8590. doi:10.1016/j.vaccine.2011.09.021. PubMed: 21939712.
24. Wentzensen N, Rodriguez AC, Viscidi R, Herrero R, Hildesheim A, et al. (2011) A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study. J Infect Dis 204: 94-102. doi:10.1093/infdis/jir209. PubMed: 21628663.
25. Safaeian M, Porras C, Schiffman M, Rodriguez AC, Wacholder S, et al. (2010) Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and-18 infections. J Natl Cancer Inst 102: 1653-1662. doi:10.1093/jnci/djq384. PubMed: 20944077.
26. Velicer C, Zhu X, Vuocolo S, Liaw KL, Saah A, (2009) Prevalence and incidence of HPV genital infection in women. Sex Transm Dis 36: 696-703. doi:10.1097/OLQ.0b013e3181ad25ff. PubMed: 19652630.
27. Ho GY, Studentsov YY, Bierman R, Burk RD, (2004) Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 13: 110-116. doi:10.1158/1055-9965.EPI-03-0191. PubMed: 14744741.
28. Viscidi RP, Kotloff KL, Clayman B, Russ K, Shapiro S, et al. (1997) Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin Diagn Lab Immunol 4: 122-126. PubMed: 9067643.
29. Syrjänen S, (2010) Current concepts on human papillomavirus infections in children. APMIS 118: 494-509. doi:10.1111/j.1600-0463.2010.02620.x. PubMed: 20553530.
30. Rice PS, Cason J, Best JM, Banatvala JE, (1999) High risk genital papillomavirus infections are spread vertically. Rev Med Virol 9: 15-21. doi:10.1002/(SICI)1099-1654(199901/03)9:1. PubMed: 10371668.
31. Sonnex C, Strauss S, Gray JJ, (1999) Detection of human papillomavirus DNA on the fingers of patients with genital warts. Sex Transm Infect 75: 317-319. doi:10.1136/sti.75.5.317. PubMed: 10616355.
32. Heim K, Hudelist G, Geier A, Szedenik H, Christensen ND, et al. (2007) Type-specific antiviral antibodies to genital human papillomavirus types in mothers and newborns. Reprod Sci 14: 806-814. doi:10.1177/1933719107309546. PubMed: 18089599.
33. Longet S, Schiller JT, Bobst M, Jichlinski P, Nardelli-Haefliger D, (2011) A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. J Virol 85: 13253-13259. doi:10.1128/JVI.06093-11. PubMed: 21976653.
34. Lu B, Viscidi RP, Wu Y, Lee JH, Nyitray AG, et al. (2012) Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men. Cancer Res 72: 676-685. doi:10.1158/1538-7445.AM2012-676. PubMed: 22123925.
35. Goldblatt D, Vaz AR, Miller E, (1998) Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis 177: 1112-1115. doi:10.1086/517407. PubMed: 9534995.
36. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, et al. (2001) Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 93: 284-292. doi:10.1093/jnci/93.4.284. PubMed: 11181775.
37. Matsumoto K, Yoshikawa H, Yasugi T, Nakagawa S, Kawana K, et al. (1999) Balance of IgG subclasses toward human papillomavirus type 16 (HPV16) L1-capsids is a possible predictor for the regression of HPV16-positive cervical intraepithelial neoplasia. Biochem Biophys Res Commun 258: 128-131. doi:10.1006/bbrc.1999.0588. PubMed: 10222247.
38. Schroeder HW Jr., Cavacini L, (2010) Structure and function of immunoglobulins. J Allergy Clin Immunol 125: S41-S52. doi:10.1016/j.jaci.2009.09.046. PubMed: 20176268.
39. Platts-Mills TA, Woodfolk JA, (2011) Allergens and their role in the allergic immune response. Immunol Rev 242: 51-68. doi:10.1111/j.1600-065X.2011.01021.x. PubMed: 21682738.